Phase II trial of PS341 (NSC 681239) in patients with advanced renal cell carcinoma

Trial Profile

Phase II trial of PS341 (NSC 681239) in patients with advanced renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Actual end date (April 2004) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Last checked against ClinicalTrials.gov record.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top